Amniotic Band: A Syndrome, Not the Rock Group

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

An elderly woman had a pressure sore on her left heel. Her history included hypertension and coronary arterial disease. The extremities showed no cyanosis, clubbing, or edema. Both feet felt cool; she had weak but palpable distal pulses on the right foot but distal pulses on the left were not palpable and could only be heard faintly with the handheld Doppler. Petechiae were seen on the dorsum of the left foot. Vital signs and platelet count were normal.

NEXT QUESTION »

For the answer, click here.

Question 4:

NEXT QUESTION »

For the answer, click here.

Question 5:

A painful rash developed at the base of the penis of a 28-year-old man. He always wore a condom during intercourse.

ANSWER KEY »

Head-To-Head Trial Shows Dynavax’s Z-1018 Rivals Shingrix for Efficacy and Tolerability

ANSWER KEY:

Question 1. F

Question 2. C

Question 3. C

Question 4. B

Question 5. D

Related Content

Grace Halsey

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Z-1018, which combines a glycoprotein E (gE) antigen and proprietary adjuvant, was evaluated in adults aged 50 to 69 and the 100 µg dose will advance to part 2 of the trial.

Amesh Adalja, MD;Sydney Jennings

Public Awareness of HPV and HPV Vaccine Remains Low, Especially in Midwest and South, Study Finds

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

August 19th 2025

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

New data shows more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

May 7th 2025

FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

August 18th 2025

COVID-19 Infection Raises Risk of Asthma and Other Respiratory Type-2 Inflammatory Diseases

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

August 15th 2025

Head-To-Head Trial Shows Dynavax’s Z-1018 Rivals Shingrix for Efficacy and Tolerability

Large US cohort study finds COVID-19 infection increases short-term risk of asthma, allergic rhinitis, and chronic rhinosinusitis, while vaccination lowers these risks.

Related Content

Grace Halsey

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Z-1018, which combines a glycoprotein E (gE) antigen and proprietary adjuvant, was evaluated in adults aged 50 to 69 and the 100 µg dose will advance to part 2 of the trial.

Amesh Adalja, MD;Sydney Jennings

Public Awareness of HPV and HPV Vaccine Remains Low, Especially in Midwest and South, Study Finds

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

August 19th 2025

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

New data shows more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

May 7th 2025

FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

August 18th 2025

COVID-19 Infection Raises Risk of Asthma and Other Respiratory Type-2 Inflammatory Diseases

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

August 15th 2025